Publications
Vedolizumab and Extraintestinal Manifestations in Inflammatory Bowel Disease
Citation
Hanzel J, Ma C, Casteele NV, Khanna R, Jairath V, Feagan BG. Vedolizumab and Extraintestinal Manifestations in Inflammatory Bowel Disease. Drugs. 2021 Feb;81(3):333-347. doi: 10.1007/s40265-020-01460-3. Erratum in: Drugs. 2021 Sep;81(14):1697. PMID: 33400241.
Abstract
In Crohn’s disease and ulcerative colitis, inflammation is not limited to the digestive tract. Extraintestinal manifestations (EIMs), which affect up to 50% of patients, can substantially impair quality of life. EIMs may parallel luminal disease activity or have an independent course. They most commonly involve the musculoskeletal system (e.g., peripheral or axial arthritis) and skin (e.g., erythema nodosum and pyoderma gangrenosum). Less commonly, the hepatobiliary tract (e.g., primary sclerosing cholangitis [PSC]) and the eye (e.g., episcleritis, scleritis, and uveitis) are involved.
